Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 StudyGilberto de Castro, Byoung Chul Cho, Dariusz M. Kowalski et al.|Journal of Clinical Oncology|2022Cited by 334
363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancerGilberto de Castro, Byoung Chul Cho, Iveta Kudaba et al.|Regular and Young Investigator Award Abstracts|2021Cited by 17